Enovis Corporation (NYSE:ENOV) Stock Has Average Target Price of $37.25

Enovis Corporation (NYSE:ENOV) has earned an average rating of “Moderate Buy” from the twelve research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $38.62.

A number of research analysts recently weighed in on ENOV shares. Needham & Company LLC raised their target price on shares of Enovis from $34.00 to $38.00 and gave the company a “buy” rating in a report on Thursday. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Wells Fargo & Company lifted their price objective on shares of Enovis from $33.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 2nd.

Insider Activity

In related news, CEO Damien Mcdonald purchased 13,035 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was bought at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the transaction, the chief executive officer owned 247,077 shares in the company, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Oliver Engert acquired 5,140 shares of Enovis stock in a transaction on Thursday, September 3rd. The shares were bought at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the purchase, the insider directly owned 61,238 shares of the company’s stock, valued at $1,191,691.48. The trade was a 9.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 23,293 shares of company stock valued at $449,599. 2.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enovis

A number of institutional investors and hedge funds have recently modified their holdings of the stock. IFP Advisors Inc increased its position in Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after acquiring an additional 1,174 shares during the last quarter. Allworth Financial LP bought a new position in Enovis in the second quarter worth approximately $36,000. Integrated Wealth Concepts LLC bought a new position in shares of Enovis during the 2nd quarter worth $39,000. Public Employees Retirement System of Ohio purchased a new position in Enovis during the 2nd quarter valued at about $48,000. Finally, SBI Securities Co. Ltd. purchased a new position in Enovis during the third quarter valued at approximately $55,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Key Stories Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 adjusted earnings were $0.88 per share, beating estimates of about $0.77 and topping $0.75 a year earlier. Revenue of $558.7 million slightly exceeded forecasts and grew 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Enovis raised its 2026 EPS guidance to $3.58–$3.79, signaling improved earnings expectations. Guidance and repurchase announcement
• Positive Sentiment: The company authorized a $200 million share-repurchase program, which could support per-share results and signal confidence in its prospects. Share-buyback announcement
• Positive Sentiment: Wells Fargo raised its target to $37 and maintained an Overweight rating; Needham lifted its target to $38 and BTIG to $42, both with Buy ratings. Wells Fargo analyst rating
• Neutral Sentiment: Canaccord lowered its price target from $45 to $42 but kept a Buy rating. Reports also highlighted product innovation and market-share gains, though market volatility remains a factor. Product innovation and share gains

Enovis Price Performance

Shares of Enovis stock opened at $27.16 on Friday. The stock has a 50 day moving average of $19.91 and a 200 day moving average of $23.09. Enovis has a 12 month low of $16.70 and a 12 month high of $32.41. The firm has a market cap of $1.57 billion, a PE ratio of -2.95 and a beta of 1.31. The company has a current ratio of 2.15, a quick ratio of 1.00 and a debt-to-equity ratio of 0.82.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.11. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The business had revenue of $558.73 million for the quarter, compared to the consensus estimate of $557.12 million. During the same quarter in the previous year, the company posted $0.75 EPS. The company’s revenue was up 1.8% compared to the same quarter last year. On average, research analysts expect that Enovis will post 3.15 EPS for the current fiscal year.

Enovis Company Profile

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.